Trial
NCT03387917
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Swiss Cancer Institute
Collaborators
—
Condition
Advanced Solid Tumors
Intervention
TLD-1
Why stopped
The premature termination is based on the unexpectedly low patient accrual to the clinical trial and the strategic considerations in the development of the TLD-1 after having included 13 out of 14 patients in the comparative PK part.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-02